Consequently, α-MG acts as a protective agent against thioacetamide-induced liver fibrosis and cirrhosis by reducing fibrotic nodules, lowering AST and ALT levels, lowering p53 expression, and ameliorating the elevated TGF-β1, α-SMA, and TIMP-1. This evidence concerns the gene TGFB1 and Hepatic fibrosis.